158744-37-7

Basic information

• Product Name: Ethyl 4(S)-(benzyloxyformamido)-3(R)-hydroxy-5-phenylpentanoate
• Synonyms: Ethyl 4(S)-(benzyloxyformamido)-3(R)-hydroxy-5-phenylpentanoate
• CAS NO: 158744-37-7
• Molecular Weight: 371.433
• Mol File: 158744-37-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Ethyl 4(S)-(benzyloxyformamido)-3(R)-hydroxy-5-phenylpentanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4(S)-(benzyloxyformamido)-3(R)-hydroxy-5-phenylpentanoate(158744-37-7)
• EPA Substance Registry System: Ethyl 4(S)-(benzyloxyformamido)-3(R)-hydroxy-5-phenylpentanoate(158744-37-7)

Safety Data

• Hazardous Substances Data: 158744-37-7(Hazardous Substances Data)

Upstream product

• 1161-13-3 N-Cbz-L-Phe 
• 64-17-5 ethanol 
• 530-62-1 1,1'-carbonyldiimidazole 
• 158744-36-6 ethyl (S)-4-benzyloxycarbonylamino-3-oxo-5-phenylpentanoate 

Downstream Products

• 136522-18-4 2-<3(S)-<amino>-2(R)-hydroxy-4-phenylbutyl>-N-tert-butyldecahydro-(4aS,8aS)-isoquinoline-3(S)-carboxamide 
• 137431-05-1 2-<3(S)-(Benzyloxyformamido)-2(R)-hydroxy-4-phenylbutyl>-N-tert-butyldecahydro-(4aS,8aS)-isoquinoline-3(S)-carboxamide 
• 137431-06-2 2-[3(S)-[(L-asparaginyl)-amino]-2(R)-hydroxy-4-phenylbutyl]-N-tert-butyl-decahydro(4aS,8aS)-isoquinoline-3(S)-carboxamide 
• 1027376-26-6 4(S)-Benzyl-3-(benzyloxycarbonyl)-2,2-dimethyl-5(R)-oxazolidineacetic acid chloride 
• 158744-41-3 4(S)-Benzyl-3-(benzyloxycarbonyl)-2,2-dimethyl-5(R)-oxazolidineacetic acid 
• 120452-06-4 3(S)-(Benzyloxyformamido)-1-bromo-4-phenyl-2(S)-butanol 
• 198020-19-8 (2R,2S)-(3S)-1,2-epoxy-3-phenylmethoxycarbonylamino-4-phenylbutane 
• 136522-17-3 cis-N-butyldecahydro-2-<2(R)-hydroxy-4-phenyl-3(S)-aminobutyl>-(4aS,8aS)-isoquinoline-3(S)-carboxamide 
• 127779-20-8 Saquinavir 
• 237056-88-1 (2S,5S,6R,10R)-5-Benzyl-10-heptyl-2-isopropyl-6-methoxymethoxy-4-methyl-1,9-dioxa-4-aza-cyclododecane-3,8,12-trione 

Relevant articles and documents

Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents

The marine natural product hapalosin and 22 analogs, which incorporated systematic substituent deletions or variations, were prepared. These compounds were evaluated in a cell-based assay for both MDR-reversing activity and general cytotoxicity. Some substituent modifications resulted in lower cytotoxicities, but most structural changes were either detrimental to or did not seriously alter the MDR-reversing activity.